| Heart Failure Treatment and Management | Lifetime | 19 | US 11 | 99.92 |
| Cardiovascular Function and Risk Factors | Lifetime | 57 | US 41 | 99.89 |
| GDF15 and Related Biomarkers | Lifetime | 3 | US 2 | 99.45 |
| IL-33, ST2, and ILC Pathways | Lifetime | 19 | US 12 | 99.71 |
| Cardiac pacing and defibrillation studies | Lifetime | 74 | US 41 | 99.70 |
| Acute Myocardial Infarction Research | Lifetime | 83 | US 52 | 99.74 |
| Diabetes Treatment and Management | Lifetime | 95 | US 44 | 99.54 |
| Cardiac Health and Mental Health | Lifetime | 66 | US 42 | 99.27 |
| Cardiac Structural Anomalies and Repair | Lifetime | 145 | US 97 | 99.49 |
| Cardiac Imaging and Diagnostics | Lifetime | 320 | US 175 | 99.46 |
| Potassium and Related Disorders | Lifetime | 28 | US 19 | 99.33 |
| Cardiac Fibrosis and Remodeling | Lifetime | 76 | US 36 | 98.66 |
| Cardiac, Anesthesia and Surgical Outcomes | Lifetime | 773 | US 385 | 98.50 |
| Cardiac Valve Diseases and Treatments | Lifetime | 555 | US 284 | 98.90 |
| Emergency and Acute Care Studies | Lifetime | 363 | US 213 | 97.98 |
| Eosinophilic Esophagitis | Lifetime | 374 | US 143 | 98.07 |
| Coronary Interventions and Diagnostics | Lifetime | 591 | US 251 | 98.33 |
| Galectins and Cancer Biology | Lifetime | 381 | US 134 | 96.30 |
| Mechanical Circulatory Support Devices | Lifetime | 769 | US 437 | 97.16 |
| Chemotherapy-induced cardiotoxicity and mitigation | Lifetime | 211 | US 119 | 95.58 |
| Macrophage Migration Inhibitory Factor | Lifetime | 325 | US 144 | 90.77 |
| Takotsubo Cardiomyopathy and Associated Phenomena | Lifetime | 245 | US 81 | 90.31 |
| Erythropoietin and Anemia Treatment | Lifetime | 760 | US 301 | 90.52 |
| Cardiovascular Function and Risk Factors | 2021-2025 | 19 | US 10 | 99.87 |
| Diabetes Treatment and Management | 2021-2025 | 26 | US 16 | 99.73 |
| Heart Failure Treatment and Management | 2021-2025 | 23 | US 13 | 99.82 |
| Acute Myocardial Infarction Research | 2021-2025 | 32 | US 12 | 99.29 |
| Cardiac pacing and defibrillation studies | 2021-2025 | 48 | US 20 | 99.26 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 69 | US 28 | 97.63 |
| Pancreatic function and diabetes | 2021-2025 | 116 | US 60 | 97.55 |
| Cardiac Imaging and Diagnostics | 2021-2025 | 279 | US 92 | 97.93 |
| Potassium and Related Disorders | 2021-2025 | 27 | US 13 | 97.68 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 197 | US 68 | 95.82 |
| Chemotherapy-induced cardiotoxicity and mitigation | 2021-2025 | 108 | US 43 | 92.40 |
| Cardiac Structural Anomalies and Repair | 2021-2025 | 843 | US 371 | 91.64 |
| Cardiomyopathy and Myosin Studies | 2021-2025 | 453 | US 158 | 90.49 |
| Cardiac Fibrosis and Remodeling | 2021-2025 | 177 | US 47 | 85.28 |
| Healthcare cost, quality, practices | 2021-2025 | 824 | US 352 | 71.73 |
| Erythropoietin and Anemia Treatment | 2021-2025 | 669 | US 172 | 59.14 |
| GDF15 and Related Biomarkers | 2021-2025 | 592 | US 152 | 54.39 |
| Sex and Gender in Healthcare | 2021-2025 | 976 | US 390 | 28.44 |